Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cardiol Therapeutics Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct art units, indicating that the company's pharmaceutical research is being reviewed in different specialized groups. The involvement of 2 distinct examiners means each case is being reviewed by a different person, allowing for independent assessment of the technical merits of each application.
GONZALEZ, LUISALBERTO is the busiest examiner for the company, with 1 pending office action. With 2 pending office actions and the distinct examiners, the workload is evenly divided, with the busiest examiner managing a portion of the cases. This distribution across 2 distinct art units and examiners requires the applicant to handle separate prosecution paths. The lack of concentration with a single examiner or art unit provides a level of diversification for the portfolio.
For a practitioner, the Biotechnology & Pharmaceuticals focus requires adapting to the specific requirements of the different art units. The 1 pending office action under the busiest examiner represents half of the active workload, making its outcome significant. The applicant must address the unique technical challenges and examiner styles present in each case. Coordinating these efforts is necessary to ensure that the company's broader pharmaceutical strategy remains consistent across the distinct examiners involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GONZALEZ, LUISALBERTO | 1 | 59.7% | +46.3% |
| TRAN, ERIC | 1 | 69.8% | +19.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265509 | STABLE ORAL CANNABIDIOL COMPOSITIONS | GONZALEZ, LUISALBERTO | — |
| 17753476 | STABLE MEDICINAL CANNABIDIOL COMPOSITIONS | TRAN, ERIC | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18265509 | STABLE ORAL CANNABIDIOL COMPOSITIONS | GONZALEZ, LUISALBERTO | 1624 | §103 | Final Rejection | — | Pending | Jun 06, 2023 |
| 17753476 | STABLE MEDICINAL CANNABIDIOL COMPOSITIONS | TRAN, ERIC | 1629 | §112Other | Non-Final OA | — | Pending | Mar 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCardiol Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Luisalberto Gonzalez has the most, with 1 of Cardiol Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
